comparemela.com

Latest Breaking News On - Intranasal racemic ketamine - Page 1 : comparemela.com

NRx Pharmaceuticals, Inc (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Thank you for standing by. This is the conference operator. Welcome to NRX Pharmaceuticals’ Third Quarter 2023 Earnings Conference Call. As a reminder, all participants are in listen-only mode. The conference is being recorded. After the presentation, there will be an opportunity […]

Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Presents a Poster on SLS-002 at the 2021 IASR/AFSP International Summit on Suicide Research

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on Part 1, the open-label portion, of the study of SLS-002 at the IASRAFSP International Summit on Suicide Research Virtual Conference. The poster titled A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.